RARasime Derya Aksoy

Rasime Derya Aksoy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rasime Derya Aksoy has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Fatma Demet Arslan

    Department of Medical Biochemistry, Faculty of Medicine , Bakırçay University , Izmir , Türkiye

    3 shared publications
  • Fatma Demet Arslan

    Faculty of Medicine, Bakırçay University, Department of Medical Biochemistry, İzmir, Turkey

    2 shared publications
  • Nisel Yılmaz

    University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Microbiology, Izmir, Turkey

    2 shared publications
  • A.ö. Koçyiğit

    Tissue Typing Laboratory, Tepecik Education and Research Hospital, Izmir, Turkey; Medical Biology and Genetics Department, Faculty of Medicine, İzmir Katip Celebi University, Izmir, Turkey

    1 shared publication
  • Asuman Birinci

    Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Samsun, Türkiye

    1 shared publication
  • Ayhan Donmez

    Department of Hematology, Ege University Medical School, İzmir, Turkey

    1 shared publication

Latest Publications

  • Evaluation of Methods and Results Used in Screening and Identification of Anti-HLA Antibodies: A Multicenter Study in Türkiye

    by Rasime Derya Aksoy, Eda Balkan, Kemal Bilgin, Asuman Birinci, Buket Şeflek Çetin, Hasan Doğan, Mehtap Doğruel, Ayhan Dönmez, Demet Gür Vural, Çiğdem Kekik Çınar, et al.

    Objective: Panel-reactive antibodies (PRA) or anti-human leucocyte antigens (anti-HLAs) are produced by the patient's immune system in response to donors during transplant procedures. Antibodies to HLA are known to develop following blood transfusion, pregnancy, and a history of transplantation. Donor-specific antibodies (DSA) arising in patient serum in response to donor-specific HLA can be detected using the single antigen bead (SAB) test. The objective of this multicentre retrospective study is to analyse the distribution of anti-HLA antibodies in Turkey, mean fluorescence intensity (MFI) values, and to assess the concordance of PRA tests across centres on a national scale. Materials and Methods: The study will include adult patients and their donors who were on the living and cadaveric waiting lists and who underwent PRA screening/identification/SAB tests between 2013-2024. Data on patients' anti-HLA antibodies and demographics will be obtained from 12 tissue typing laboratories. Tests and MFI values will be recorded. The data will undergo rigorous testing for statistical significance using SPSS version 23.0, with a p-value <0.05. Results: This study will reveal the distribution of anti-HLA antibodies across Turkey for the first time, and the effects of sensitization factors will be analysed. The correlation between Class I and II antibody positivity, MFI levels, and demographic data will be evaluated. Discussion: The findings of this study will contribute to advancing laboratory consistency and establishing national test standardisation. It is hypothesized that the obtained data may also provide insights into updating the organ allocation system to include antibody testing. The comparison of PRA tests, SAB methods, and the MFI values will provide a new perspective on laboratory and clinical evaluation. This study aims to enhance the efficacy of patient-donor matching through the identification of shared criteria for pre-transplant immunological risk assessment within the national context. Keywords: MFI, PRA screening/identification, SAB, transplantation

  • Open Access

    Lipemia and Serum Index–Related Interference in Luminex-Based Anti-HLA Antibody Detection

    by Rasime Derya Aksoy, Fatma Demet Arslan

    BackgroundLuminex bead-based solid-phase immunoassays (SFIA) are the gold standard for anti–human leukocyte antigen (HLA) antibody detection in transplantation immunology. However, preanalytical interferences may compromise assay validity. Although automated hemolysis, icterus, and lipemia (HIL) indices are routinely used to assess sample quality, their relevance for predicting interference in Luminex-based HLA antibody testing remains unclear.MethodsA total of 1,308 patient samples were retrospectively evaluated using Luminex SFIA. Internal control bead mean fluorescence intensity (MFI) values were assessed according to manufacturer-defined criteria. Samples with control bead deviations were analyzed in relation to automated HIL indices and categorized into four interference profiles based on control bead behavior. Control bead normalization ratios and correlation analyses were performed.ResultsControl bead MFI values outside acceptable ranges were observed in 125 samples (9.7%). After exclusion of 16 samples, 109 were included in the final analysis. Elevated lipemia indices were associated with assay interference in two groups, manifesting as signal amplification or signal quenching. Notably, nearly half of the deviated samples showed marked signal suppression despite normal HIL indices, consistent with silent interference. Another interference profile demonstrated pronounced control bead signal elevation in the absence of abnormal HIL indices, indicating an index-independent matrix effect.ConclusionLipemia represents an underrecognized source of interference in Luminex-based HLA antibody testing. Automated HIL indices alone are insufficient to identify all compromised samples. Systematic monitoring of internal control bead values may improve detection of silent and index-independent interferences and enhance analytical accuracy.

  • Assessment of mimicking by EBV-CMV immunoglobulin M of anti-HLA antibodies

    by Rasime Derya Güleç, Fatma Demet Arslan, Berk Özyılmaz, Nisel Yılmaz, Sevgi Yılmaz Hancı, Şükran Köse

  • Open Access

    Frequencies of HLA Alleles in Patients with Acute Lymphoblastic and Myeloid Leukemia

    by Rasime Derya Güleç, Fatma Demet Arslan

    Objective: Our objective was to investigate the potential correlation between human leukocyte antigens (HLA) - specifically, HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes - and patients diagnosed with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Material and Methods: We conducted an analysis of HLA allele frequencies among 393 patients with ALL, 431 patients with AML, and a control group comprising 564 healthy donors. Additionally, we explored the variation in HLA allele distribution between pediatric and adult patients diagnosed with ALL. Results: In comparison to the donor group, a heightened frequency of HLA-A*32 antigen was observed in AML patients (p=0.015, OR: 1.682). Conversely, the frequencies of HLA-B*55 (p=0.027, OR: 0.545) in ALL patients, HLA-B*14 (p=0.023, OR: 0.397), and HLA-B*55 (p=0.04, OR: 0.604) in AML patients were notably diminished. Notably, there were no discernible differences in HLA Class II allele frequency and analysis between the patient and control groups. Moreover, a significant distinction in the frequencies of HLA-A*25 (p=0.019, OR: 8.426) and DRB1*04 (p=0.049, OR: 1.491) was identified between pediatric patients (n=165) and adult patients (n=228) with ALL. Conclusion: The findings indicate that HLA-A*32 might serve as a genetic predisposing factor for AML, and HLA-A*25 and DRB1*04 could be potential genetic risk factors for pediatric ALL patients. Conversely, HLA-B*55 appears to be a potential protective factor against both forms of acute leukemia.


  • Could presepsin be an alternative marker in the early diagnosis of sepsis in COVID-19?

    by Rasime Derya Güleç, Fatma Demet Arslan, Taner Çalışkan, Nimet Şenoǧlu, Nisel Yılmaz, Sabri Atalay, İbrahim Pirim

    In critical patients with Coronavirus Disease (COVID-19), we investigated the diagnostic value of presepsin in the early diagnosis of superinfection with sepsis, and the effect of antibiotic treatment (AT) in the levels of presepsin and procalcitonin and C-reactive protein. A total of 68 critical patients with sepsis and septic shock in the intensive care unit and 20 outpatients (control group) with COVID-19 were taken. ICU patients (n = 68) were further divided into three groups. C(−)AT(−) had negative blood or tracheal aspirate cultures (C) and not AT on admission to ICU (n = 18), C(−)AT(+) had negative C and AT on admission to intensive care unit (n = 31) and C(+) had positive C (n = 19). Presepsin, procalcitonin, C-reactive protein results were compared between the groups. There were no significant relationships between presepsin levels with sepsis, septic shock, mortality, or length of stay in ICU in patients with COVID-19. For procalcitonin and C-reactive protein levels in C(−)AT(+) and C(+) groups were significantly higher than in control and C(−)AT(−) groups (p < .001). C-reactive protein levels in C(−)AT(−) group were significantly higher than in the control group (p < .001). PCT and CRP, there was no difference between C(−)AT(+) and C(+) groups, and procalcitonin there was no difference between control and C(−)AT(−) groups. Presepsin was not found as a useful biomarker for the prediction of sepsis in COVID-19 patients. These study findings indicate that procalcitonin and C-reactive protein may be an indicator of an early diagnostic marker for superinfection in critical COVID-19 patients.


  • Open Access

    β-Thalassemia Mutation At Codon 37 (TGG>>TGA) Detected In A Turkish Family

    by Derya Güleç, Sibel Bilgili, Nuriye Uzuncan, Giray Bozkaya, Nur Soyer, Baysal Karaca